Effects of Chungsinoryungsan, a polyherbal complex, on the pharmacokinetic profiles of perindopril in rats

Kang,Seok‑Bong; Shon,Ho‑Sang; Park,Soo‑Jin; Song,Chang‑Hyun; Ku,Sae‑Kwang

doi:10.3892/br.2014.330

Effects of Chungsinoryungsan, a polyherbal complex, on the pharmacokinetic profiles of perindopril in rats

Authors:
- Seok‑Bong Kang
- Ho‑Sang Shon
- Soo‑Jin Park
- Chang‑Hyun Song
- Sae‑Kwang Ku
View Affiliations

Affiliations: Department of Nephrology, College of Korean Medicine, Daegu Haany University, Gyeongsan, North Gyeongsang 712‑715, Republic of Korea, Department of Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu 705‑718, Republic of Korea, Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, Gyeongsan, North Gyeongsang 712‑715, Republic of Korea
Published online on: August 5, 2014 https://doi.org/10.3892/br.2014.330
Pages: 855-860

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For sufficient antihypertension with less adverse effects, numerous clinical trials have recommended combination therapy using two or more hypertensive drugs. Chungsinoryungsan (CSORS) is a polyherbal complex based on oriental medicine, which has shown therapeutic potentials for antihypertension and additional renal improvement. Therefore, the affect of CSORS on the pharmacokinetic profiles of perindopril, an antihypertensive drug, was analyzed as a novel combination of hypertensive drugs. Rats received perindopril with CSORS as the combination or distilled water as the control. The co‑administration of perindopril with CSORS or distilled water was performed by single dosing or repeated dosing for a week at a 2-h interval. The analyzed pharmacokinetic parameters included peak concentration (Cmax), time to reach the Cmax (Tmax), area under the plasma concentration‑time curve, terminal half‑life (t1/2) and mean residence time to infinity (MRTinf). In the single oral co‑administration within 5 min, the pharmacokinetics of perindopril demonstrated an increased Tmax and MRTinf but reduced t1/2 in the combination compared to the control treatment, indicating drug‑drug interactions between perindopril and CSORS. However, in the repeated co-administration for a week at a 2-h interval, which was more than perindopril MRTinf in the control treatment (1.5±0.1 h), the initial co‑administration showed no differences in the pharmacokinetics between the combination and control treatments. Furthermore, the repeated co‑administration also showed no differences between the combination and control treatment. The results indicate that CSORS can be co‑administered at a 2‑h interval that was more than perindopril MRTinf and further clinical studies may provide detailed information for developing a drug regimen that generates enhanced combination effects of CSORS with hypertensive drugs.

View Figures

View References

1	Kearney PM, Whelton M, Reynolds K, Whelton PK and He J: Worldwide prevalence of hypertension: a systematic review. J Hypertens. 22:11–19. 2004. View Article : Google Scholar : PubMed/NCBI
2	Nesbitt SD: Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction. J Clin Hypertens (Greenwich). 9(Suppl 4): 26–32. 2007. View Article : Google Scholar : PubMed/NCBI
3	Salahuddin A, Mushtaq M and Materson BJ: Combination therapy for hypertension 2013: an update. J Am Soc Hypertens. 7:401–407. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nakao N, Yoshimura A, Morita H, Takada M, Kayano T and Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 361:117–124. 2003. View Article : Google Scholar
5	Todd PA and Fitton A: Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 42:90–114. 1991.PubMed/NCBI
6	Cleland JG, Tendera M, Adamus J, et al: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 27:2338–2345. 2006. View Article : Google Scholar : PubMed/NCBI
7	Waeber B, de la Sierra A and Ruilope LM: The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drugs. 9:283–291. 2009. View Article : Google Scholar : PubMed/NCBI
8	Santa Cruz Biotechnology. Material safety data sheet of perindopril (sc-205799). http://pdf.analysis1.org/perindopril-santa-cruz-biotechnology-w1778uri. Accessed on December 6, 2010
9	Clark LT: Safety profile of perindopril. Am J Cardiol. 88:36i–40i. 2001. View Article : Google Scholar : PubMed/NCBI
10	Ji HF, Li XJ and Zhang HY: Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 10:194–200. 2009.PubMed/NCBI
11	Scheid V, Bensky B, Ellis A and Barolet R: Chinese Herbal Medicine: Formulas and Strategies. 2nd edition. Eastland Press; Seattle, WA: pp. 724–728. 2009
12	Liu IM, Tzeng TF, Liou SS and Chang CJ: The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription. J Ethnopharmacol. 124:211–218. 2009. View Article : Google Scholar : PubMed/NCBI
13	He L, Rong X, Jiang JM, Liu PQ and Li Y: Amelioration of anti-cancer agent adriamycin-induced nephrotic syndrome in rats by Wulingsan (Gorei-San), a blended traditional Chinese herbal medicine. Food Chem Toxicol. 46:1452–1460. 2008. View Article : Google Scholar
14	Ding XQ, Pan Y, Wang X, Ma YX and Kong LD: Wuling san ameliorates urate under-excretion and renal dysfunction in hyperuricemic mice. Chin J Nat Med. 11:214–221. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhu YP: Chinese Materia Medica: Chemistry, Pharmacology, and Applications. Harwood Academic; Amsterdam: pp. 311–344. 1998
16	DeVane CL: Pharmacokinetics (2nd edition, revised and expanded), M. Gibaldi and D. Perrier (vol. 15 of Drugs and the Pharmaceutical sciences), Marcel Dekker, New York, 1982. Biopharmaceutics and Drug Disposition. 4:201. 1983. View Article : Google Scholar
17	Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level - time curve. J Pharmacokinet Biopharm. 6:539–546. 1978. View Article : Google Scholar : PubMed/NCBI
18	Brown CL, Backhouse CI, Grippat JC and Santoni JP: The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol. 39:327–332. 1990. View Article : Google Scholar : PubMed/NCBI
19	Scalbert E, Abdon D, Devissaguet M and Juggi JS: Interaction between an angiotensin converting enzyme inhibitor, perindopril, and a thiazide diuretic in the spontaneously hypertensive rat. Can J Cardiol. 8:381–386. 1992.PubMed/NCBI
20	Morin JP, Thomas N, Toutain H, Borghi H and Fillastre JP: Treatment with an angiotensin converting enzyme inhibitor may increase the nephrotoxicity of gentamicin in rats. Pathol Biol (Paris). 37:652–656. 1989.(In French).
21	Vipond AJ, Bakewell S, Telford R and Nicholls AJ: Lithium toxicity. Anaesthesia. 51:1156–1158. 1996. View Article : Google Scholar
22	Christensen S, Shalmi M, Hansen AK and Marcussen N: Effects of perindopril and hydrochlorothiazide on the long-term progression of lithium-induced chronic renal failure in rats. Pharmacol Toxicol. 80:132–141. 1997. View Article : Google Scholar : PubMed/NCBI
23	Vandenburg MJ, Stephens JD, Resplandy G, Dews IM, Robinson J and Desche P: Digoxin pharmacokinetics and perindopril in heart failure patients. J Clin Pharmacol. 33:146–149. 1993. View Article : Google Scholar : PubMed/NCBI
24	Johnston D and Duffin D: Drug-patient interactions and their relevance in the treatment of heart failure. Am J Cardiol. 70:109C–112C. 1992. View Article : Google Scholar : PubMed/NCBI
25	Setiawati E, Deniati SH, Yunaidi DA, et al: Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers. Arzneimittelforschung. 61:234–238. 2011. View Article : Google Scholar : PubMed/NCBI
26	Devissaguet JP, Ammoury N, Devissaguet M and Perret L: Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam Clin Pharmacol. 4:175–189. 1990. View Article : Google Scholar : PubMed/NCBI
27	Georgakakou S, Kazanis M and Panderi I: Hydrophilic interaction liquid chromatography/positive ion electrospray ionization mass spectrometry method for the quantification of perindopril and its main metabolite in human plasma. Anal Bioanal Chem. 397:2161–2170. 2010. View Article : Google Scholar
28	Lecocq B, Funck-Brentano C, Lecocq V, et al: Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther. 47:397–402. 1990. View Article : Google Scholar : PubMed/NCBI
29	Grislain L, Mocquard MT, Dabe JF, et al: Interspecies comparison of the metabolic pathways of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor. Xenobiotica. 20:787–800. 1990. View Article : Google Scholar : PubMed/NCBI
30	Begg EJ, Robson RA, Bailey RR, Lynn KL, Frank GJ and Olson SC: The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. Br J Clin Pharmacol. 30:213–220. 1990. View Article : Google Scholar : PubMed/NCBI
31	Resplandy G and Genissel P: Pharmacokinetics of perindopril in high-risk populations. J Cardiovasc Pharmacol. 18(Suppl 7): S9–S18. 1991. View Article : Google Scholar : PubMed/NCBI
32	Parker E, Aarons L, Rowland M and Resplandy G: The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. Eur J Pharm Sci. 26:104–113. 2005. View Article : Google Scholar : PubMed/NCBI